Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | CTSA | P10619 | 9/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466496 | 0.90 | PDE4B (0.45) | PDE4DPDE4BCTSASLC6A9 | |
| SCHEMBL3466491 | 0.90 | PDE4B (0.45) | PDE4DPDE4BCTSASLC6A9 | |
| SCHEMBL3467286 | 0.86 | PDE4D (0.56) | PDE4DPDE4BCTSASLC6A9PTGDR2 | |
| SCHEMBL8027459 | 0.86 | PDE4D (0.38) | PDE4DPDE4BSLC6A9 | |
| SCHEMBL27923754 | 0.82 | CTSA (0.41) | PDE4DCTSASLC6A9HTTPTGDR2 | |
| SCHEMBL3467205 | 0.81 | PDE4D (0.61) | PDE4DPDE4BCTSASLC6A9 | |
| SCHEMBL3795872 | 0.79 | PDE4D (0.61) | PDE4DPDE4BCTSA | |
| SCHEMBL3788986 | 0.79 | PDE4D (0.58) | PDE4DPDE4BCTSA | |
| SCHEMBL3465781 | 0.79 | PDE4D (0.63) | PDE4DPDE4BCTSA | |
| SCHEMBL3465831 | 0.78 | SLC6A9 (0.46) | PDE4DPDE4BCTSASLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2628727-A2 | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | Decode Genetics EHF (IS) | 2013-08-21 | — | — | EP | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4D 7/4885PDE4B 2/4885CTSA 4056/4885 |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | PDE4D 7/4885PDE4B 2/4885CTSA 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.